CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Jiang, Lan ^a   Deng, Jieqiong ^a   Zhu, Xun ^b   Zheng, Jian ^a   You, Yonghe ^a   Li, Na ^a   Wu, Hongchun ^a   Lu, Jiachun ^c   Zhou, Yifeng ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; 3' UNTRANSLATED REGION; HERMES ANTIGEN; MICRORNA; MIRN509 MICRORNA, HUMAN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CD44 GENE; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; 3' UNTRANSLATED REGION; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST TUMOR; CHINA; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS;

3' UNTRANSLATED REGIONS; ADULT; AGED; ALLELES; ANTIGENS, CD44; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHINA; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MICRORNAS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84863651864     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3225     Document Type: Article

References (36)

1. Sariego J. Breast cancer in the young patient. Am Surg 2010, 76:1397-1400.
2. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS, . ABREAST Investigators The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005, 6:391-401. 10.3816/CBC.2005.n.043, 16381622, ABREAST Investigators.
3. Feig SA, Hendrick RE. Radiation risk from screening mammography of women aged 40-49 years. J Natl Cancer Inst Monogr 1997, 119-124.
4. Boffetta P, Hashibe M, La Vecchia C, Zatonski W, Rehm J. The burden of cancer attributable to alcohol drinking. Int J Cancer 2006, 119:884-887. 10.1002/ijc.21903, 16557583.
5. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006, 98:1767-1776. 10.1093/jnci/djj494, 17179478.
6. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282. 10.1056/NEJMra050776, 16421368.
7. Andrieu N, Clavel F, Auquier A, Le MG, Gairard B, Piana L, Bremond A, Lansac J, Flamant R, Renaud R. Variations in the risk of breast cancer associated with a family history of breast cancer according to age at onset and reproductive factors. J Clin Epidemiol 1993, 46:973-980. 10.1016/0895-4356(93)90164-V, 8263582.
8. Sales KM, Winslet MC, Seifalian AM. Stem cells and cancer: an overview. Stem Cell Rev 2007, 3:249-255. 10.1007/s12015-007-9002-0, 17955391.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
10. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23:675-699. 10.1146/annurev.cellbio.22.010305.104154, 17645413.
11. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 2008, 8:784-804. 10.2174/156652408786733667, 19075676.
12. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999, 52:189-196. 10.1136/mp.52.4.189, 395698, 10694938.
13. Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004, 35:211-231.
14. Herrera-Gayol A, Jothy S. Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol 1999, 66:149-156. 10.1006/exmp.1999.2251, 10409443.
15. Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005, 310:205-217. 10.1016/j.yexcr.2005.07.026, 16125700.
16. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995, 345:615-619. 10.1016/S0140-6736(95)90521-9, 7534855.
17. Dall P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P, Ponta H. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995, 60:471-477. 10.1002/ijc.2910600408, 7530237.
18. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Bocker W. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 1998, 33:107-116. 10.1046/j.1365-2559.1998.00472.x, 9762542.
19. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, Cheung VG. Genetic analysis of genome-wide variation in human gene expression. Nature 2004, 430:743-747. 10.1038/nature02797, 2966974, 15269782.
20. Zhou J, Nagarkatti PS, Zhong Y, Zhang J, Nagarkatti M. Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer. Eur J Cancer Prev 2011, 20:396-402. 10.1097/CEJ.0b013e3283463943, 21804359.
21. Jiang L, Zhang C, Li Y, Yu X, Zheng J, Zou P, Bin X, Lu J, Zhou Y. A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. Breast Cancer Res Treat 2011, 126:487-495. 10.1007/s10549-010-1094-6, 20683652.
22. Zheng J, Liu B, Zhang L, Jiang L, Huang B, You Y, Jiang Q, Zhang S, Lu J, Zhou Y. The protective role of polymorphism MKK4 -1304 T>G in nasopharyngeal carcinoma is modulated by Epstein-Barr virus' infection status. Int J Cancer 2012, 130:1981-1990. 10.1002/ijc.26253, 21702039.
23. Jurinke C, Oeth P, van den Boom D. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Mol Biotechnol 2004, 26:147-164. 10.1385/MB:26:2:147, 14764940.
24. Teng DH, Perry WL, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, Janecki T, Leavitt A, Mitchell JT, Pero R, Sexton D, Schroeder M, Su PH, Swedlund B, Kyriakis JM, Avruch J, Bartel P, Wong AK, Tavtigian SV. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997, 57:4177-4182.
25. Lu J, Wang LE, Xiong P, Sturgis EM, Spitz MR, Wei Q. 172G>T variant in the 5' untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. Carcinogenesis 2007, 28:988-994.
26. Lu J, Yang L, Zhao H, Liu B, Li Y, Wu H, Li Q, Zeng B, Wang Y, Ji W, Zhou Y. The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. Hum Mutat 2011, 32:1299-1308. 10.1002/humu.21574, 21850685.
27. Goodfellow PN, Banting G, Wiles MV, Tunnacliffe A, Parkar M, Solomon E, Dalchau R, Fabre JW. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol 1982, 12:659-663. 10.1002/eji.1830120807, 7140811.
28. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992, 89:12160-12164. 10.1073/pnas.89.24.12160, 50718, 1465456.
29. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005, 65:6755-6763. 10.1158/0008-5472.CAN-05-0863, 16061657.
30. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 2003, 278:29420-29434. 10.1074/jbc.M301885200, 12748184.
31. Bourguignon LY. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 2001, 6:287-297. 10.1023/A:1011371523994, 11547898.
32. Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 2010, 70:4624-4633. 10.1158/0008-5472.CAN-09-3619, 20484027.
33. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ, Lee WH. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 2009, 4:e8377. 10.1371/journal.pone.0008377, 2793431, 20027313.
34. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001, 11:339-352. 10.1006/scbi.2001.0389, 11562176.
35. Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999, 17:3064-3074.
36. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004, 15:193-197. 10.1016/j.tem.2004.05.011, 15223047.